Cargando…

Atypical BRAF and NRAS Mutations in Mucosal Melanoma

Primary mucosal melanomas represent a minority of melanomas, but have a significantly worse prognosis than cutaneous melanomas. A better characterization of the molecular pathogenesis of this melanoma subtype could help us understand the risk factors associated with the development of mucosal melano...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dumaz, Nicolas, Jouenne, Fanélie, Delyon, Julie, Mourah, Samia, Bensussan, Armand, Lebbé, Céleste
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721527/ https://www.ncbi.nlm.nih.gov/pubmed/31398831 http://dx.doi.org/10.3390/cancers11081133

Ejemplares similares

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care
por: Louveau, Baptiste, et al.
Publicado: (2019)

Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma
por: Reger de Moura, Coralie, et al.
Publicado: (2019)

A targeted genomic alteration analysis predicts survival of melanoma patients under BRAF inhibitors
por: Louveau, Baptiste, et al.
Publicado: (2019)

FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma
por: Tétu, Pauline, et al.
Publicado: (2020)

CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker
por: Landras, Alexandra, et al.
Publicado: (2019)

Discoidin Domain Receptors in Melanoma: Potential Therapeutic Targets to Overcome MAPK Inhibitor Resistance
por: Reger de Moura, Coralie, et al.
Publicado: (2020)

Validation of a preclinical model for assessment of drug efficacy in melanoma
por: Delyon, Julie, et al.
Publicado: (2016)

Correction: Validation of a preclinical model for assessment of drug efficacy in melanoma
por: Julie, Delyon, et al.
Publicado: (2016)

KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases
por: Zebary, A, et al.
Publicado: (2013)

BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma
por: Chiappetta, Caterina, et al.
Publicado: (2015)

KIT, NRAS, BRAF and FMNL2 mutations in oral mucosal melanoma and a systematic review of the literature
por: Chen, Feng, et al.
Publicado: (2018)

The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma
por: Gauci, Marie-Léa, et al.
Publicado: (2022)

Many Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas
por: Vachtenheim, Jiri, et al.
Publicado: (2021)

NRAS and BRAF Mutations in Melanoma-Associated Nevi and Uninvolved Nevi
por: Tschandl, Philipp, et al.
Publicado: (2013)

Lack of evidence for the involvement of Merkel cell polyomavirus in pulmonary Langerhans cell histiocytosis
por: Jouenne, Fanélie, et al.
Publicado: (2020)

Clinical value of early detection of circulating tumour DNA-BRAF(V600mut) in patients with metastatic melanoma treated with a BRAF inhibitor
por: Louveau, Baptiste, et al.
Publicado: (2017)

RICTOR Affects Melanoma Tumorigenesis and Its Resistance to Targeted Therapy
por: Jebali, Ahlem, et al.
Publicado: (2021)

Prognostic Roles of BRAF, KIT, NRAS, IGF2R and SF3B1 Mutations in Mucosal Melanomas
por: Wróblewska, Joanna P., et al.
Publicado: (2021)

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
por: Colombino, Maria, et al.
Publicado: (2013)

Prevalence of BRAF, NRAS and c-KIT Mutations in Slovenian Patients with Advanced Melanoma
por: Moltara, Maja Ebert, et al.
Publicado: (2018)

Imaging Mass Spectrometry for the Classification of Melanoma Based on BRAF/NRAS Mutational Status
por: Casadonte, Rita, et al.
Publicado: (2023)

Unmasking the tumourigenic role of SIN1/MAPKAP1 in the mTOR complex 2
por: Ezine, Emilien, et al.
Publicado: (2023)

A Novel Case of Gorlin Syndrome Mosaicism Involving an SMO Gene Mutation: Clinical, Histological and Molecular Analysis of Basaloid Tumours
por: IGHILAHRIZ, Meriem, et al.
Publicado: (2021)

Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population
por: Gutiérrez-Castañeda, Luz D., et al.
Publicado: (2020)

Endemic Kaposi’s Sarcoma
por: Zeinaty, Perla El, et al.
Publicado: (2023)

Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas
por: Hirata, Amanda S., et al.
Publicado: (2021)

TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation
por: Vallarelli, Andrelou F., et al.
Publicado: (2016)

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
por: Manca, Antonella, et al.
Publicado: (2015)

BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi
por: Francis, Jasmine H., et al.
Publicado: (2018)

Malignant Melanoma with Concurrent BRAF E586K and NRAS Q81K Mutations
por: Shackelford, Rodney, et al.
Publicado: (2014)

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
por: Heppt, Markus V., et al.
Publicado: (2017)

UVB mutagenesis differs in Nras- and Braf-mutant mouse models of melanoma
por: Bowman, Robert L, et al.
Publicado: (2021)

Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation
por: Murphy, Brandon M., et al.
Publicado: (2022)

Increased risk of brain metastases among patients with melanoma and PROM2 expression in metastatic lymph nodes
por: Nguyen, Thuy Thi, et al.
Publicado: (2020)

Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi
por: Jansen, Philipp, et al.
Publicado: (2019)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma
por: Conway, Caroline, et al.
Publicado: (2010)

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
por: Carlino, M S, et al.
Publicado: (2014)

Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients
por: Long-Mira, Elodie, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o1bln5d22nd90278co9bmnot4e